Drugs / Dendritic Cell Vaccination
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00715832 | May 2008 → Feb 2010 | breast cancer | Southern Cancer Center | Unknown | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05765084 | Feb 2023 → Oct 2027 expected | malignant pleural mesothelioma | University Hospital, Antwerp | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02649829 | Oct 2017 → Mar 2025 | malignant pleural mesothelioma | University Hospital, Antwerp | Completed | No outcome recorded |
| Phase 1/2 | NCT00879489 | May 2008 → Mar 2011 | breast cancer | Quantum Immunologics, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT00125749 | Jul 2005 → Jun 2007 | melanoma, metastatic neoplasm | Baylor Research Institute | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00965224 | Jan 2010 → Dec 2014 | acute myeloid leukemia, chronic myeloid leukemia, plasma cell myeloma | Zwi Berneman | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dendritic Cell Vaccination | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00879489 ↗ |
| Known as | WT1/DC vaccines | “WT1/DC vaccines (8-10 x 10\^6 cells in 500 μL saline solution with 5% human albumin) will be administered through intradermal injection at 5 sites (100 μL/site)” NCT05765084 ↗ |
| Modality | Vaccine | “a novel dendritic cell (DC) vaccine” NCT00125749 ↗ |
| Target | WT1 | “vaccination with dendritic cells (DCs) electroporated with Wilms' tumor 1 (WT1) messenger RNA (mRNA)” PMID 28830889 ↗ Aug 2017 |